BLINATUMOMAB IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: MECHANISM OF ACTION, CLINICAL RELEVANCE, AND EMERGING THERAPEUTIC PERSPECTIVES
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5637Keywords:
Blinatumomab, Acute Lymphoblastic Leukemia, Immunotherapy, CD19, BiTE, Pediatric OncologyAbstract
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, and despite significant improvements in survival with intensive chemotherapy, relapse and minimal residual disease (MRD) remain major clinical challenges.
Blinatumomab is a bispecific T-cell engager (BiTE) antibody targeting CD19-positive B-cell precursor ALL. By simultaneously binding CD3 on T lymphocytes and CD19 on leukemic cells, it enables major histocompatibility complex (MHC)-independent activation of cytotoxic T cells and targeted elimination of malignant cells.
Clinical studies have demonstrated that blinatumomab is effective in inducing remission in relapsed or refractory pediatric ALL and in achieving molecular remission in MRD-positive patients. Compared with conventional chemotherapy, it shows improved efficacy and a more favorable toxicity profile, although cytokine release syndrome and neurotoxicity remain clinically relevant adverse events.
Blinatumomab is increasingly used as a bridge to hematopoietic stem cell transplantation and is being investigated in combination regimens and earlier treatment settings. However, therapeutic resistance, including CD19 antigen loss and T-cell dysfunction, remains a limitation.
Overall, blinatumomab represents a significant advancement in immunotherapy for pediatric ALL, bridging conventional chemotherapy and cellular therapies such as CAR-T.
References
Pui, C. H., Robison, L. L., & Look, A. T. (2008). Acute lymphoblastic leukaemia. The Lancet, 371(9617), 1030–1043. https://doi.org/10.1016/S0140-6736(08)60457-2
Hunger, S. P., & Mullighan, C. G. (2015). Acute lymphoblastic leukemia in children. The New England Journal of Medicine, 373(16), 1541–1552. https://doi.org/10.1056/NEJMra1400972
Szczepański, T. (2022). Ostra białaczka limfoblastyczna u dzieci. In J. Styczyński & M. Matysiak (Eds.), Hematologia i onkologia dziecięca dla lekarzy praktyków (pp. 257–259). Wydawnictwo Czelej.
Campana, D. (2010). Minimal residual disease in acute lymphoblastic leukemia. Hematology. American Society of Hematology. Education Program, 2010(1), 7–12. https://doi.org/10.1182/asheducation-2010.1.7
Al-Mawali, A., Gillis, D., Hissaria, P., & Lewis, I. (2008). Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. American Journal of Clinical Pathology, 129(6), 934–945. https://doi.org/10.1309/FY0UMAMM91VPMR2W
Kantarjian, H., Stein, A., Gökbuget, N., et al. (2017). Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. The New England Journal of Medicine, 376(9), 836–847. https://doi.org/10.1056/NEJMoa1609783
Bargou, R., Leo, E., Zugmaier, G., et al. (2008). Tumor regression in cancer patients by very low doses of a T cell–engaging antibody. Science, 321(5891), 974–977. https://doi.org/10.1126/science.1158545
Offner, S., Hofmeister, R., Romaniuk, A., et al. (2006). Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Molecular Immunology, 43(6), 763–771. https://doi.org/10.1016/j.molimm.2005.03.007
Dreier, T., Lorenczewski, G., Brandl, C., et al. (2002). Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Journal of Immunology, 168(11), 5540–5547. https://doi.org/10.4049/jimmunol.168.11.5540
Klinger, M., Brandl, C., Zugmaier, G., et al. (2012). Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Leukemia, 26(6), 1215–1221. https://doi.org/10.1038/leu.2011.158
U.S. Food and Drug Administration. (2024). FDA approves blinatumomab as consolidation therapy for B-ALL. https://www.fda.gov
von Stackelberg, A., Locatelli, F., Zugmaier, G., et al. (2016). Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Journal of Clinical Oncology, 34(36), 4381–4389. https://doi.org/10.1200/JCO.2016.67.3301
Brown, P. A., Ji, L., Xu, X., et al. (2021). Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA, 325(9), 833–842. https://doi.org/10.1001/jama.2021.0669
Topp, M. S., Gökbuget, N., Stein, A. S., et al. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. The Lancet Oncology, 16(1), 57–66. https://doi.org/10.1016/S1470-2045(14)71170-2
Lee, D. W., Gardner, R., Porter, D. L., et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2), 188–195. https://doi.org/10.1182/blood-2014-05-552729
Zugmaier, G., Gökbuget, N., Klinger, M., et al. (2015). Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood, 126(24), 2578–2584. https://doi.org/10.1182/blood-2015-06-650986
Gökbuget, N., Dombret, H., Bonifacio, M., et al. (2017). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood, 129(12), 1602–1609. https://doi.org/10.1182/blood-2016-08-737379
Orlando, E. J., Han, X., Tribouley, C., et al. (2018). Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine, 24(10), 1504–1506. https://doi.org/10.1038/s41591-018-0146-z
June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. The New England Journal of Medicine, 379(1), 64–73. https://doi.org/10.1056/NEJMra1706169
Grupp, S. A., Kalos, M., Barrett, D., et al. (2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. The New England Journal of Medicine, 368(16), 1509–1518. https://doi.org/10.1056/NEJMoa1215134
Bassan, R., & Hoelzer, D. (2011). Modern therapy of acute lymphoblastic leukemia. Journal of Clinical Oncology, 29(5), 532–543. https://doi.org/10.1200/JCO.2010.30.1382
Kantarjian, H., Stelljes, M., Martinelli, G., et al. (2016). Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. The New England Journal of Medicine, 375(8), 740–753. https://doi.org/10.1056/NEJMoa1509277
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ewa Jachimczak, Vanessa Gąsiorowska, Paulina Jaruga, Karolina Grodkowska, Ewa Wojtanowska, Julia Kozicka, Julia Paczyna, Marcin Mazur, Natalia Smyczyńska, Mateusz Michalak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
